Indium (111in) Oxinate Curium Netherlands

Indium-111 oxine, the active ingredient in Indium (111in) Oxinate Curium Netherlands, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed to label leukocytes and other cells, enabling visualization of infection, inflammation, and selected tumors in patients undergoing diagnostic imaging.

GNH USA supplies Indium (111in) Oxinate Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality and regulatory compliance throughout the supply chain.

Indium-111 oxine is used in nuclear medicine for cell labeling and imaging of infectious, inflammatory, and neoplastic processes. - Infection detection: enables visualization of sites of bacterial or fungal infection by labeling patient leukocytes. - Inflammation assessment: facilitates imaging of inflammatory disorders such as vasculitis or sarcoidosis. - Tumor imaging: allows targeted imaging of certain tumors when appropriate cell labeling is performed.

Adverse reactions are generally related to the injection procedure and radiation exposure.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Transient flushing or warmth: brief sensation of heat following administration. - Nausea or mild headache: occasional short‑lived symptoms.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rare but requires immediate medical attention. - Radiation‑induced tissue injury: high localized doses may cause tissue damage. - Hemodynamic instability: hypotension or arrhythmia in susceptible patients.

Use of Indium-111 oxine requires careful consideration of radiation safety and patient condition. - Pregnancy: avoid unless benefits outweigh potential fetal radiation risk. - Breastfeeding: discontinue nursing for an appropriate period after administration. - Renal impairment: monitor renal function as excretion is primarily renal. - Concomitant immunosuppressive therapy: may alter leukocyte labeling efficiency. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Radiopharmaceuticals can interact with other agents that affect cell labeling or radiation exposure.

Major Interactions (Avoid): - Concurrent administration of other gamma‑emitting radiotracers: may interfere with image interpretation. - High‑dose chelating agents (e.g., EDTA): can strip indium from labeled cells. - Therapeutic radiation therapy performed within 24 hours: increases cumulative radiation dose.

Moderate Interactions (Monitor Closely): - Corticosteroids or immunosuppressants: may reduce leukocyte labeling efficiency. - Anticoagulants: monitor for bleeding at injection site. - Contrast agents used in CT/MRI: schedule imaging to avoid overlap with scintigraphy.